Details
| Stereochemistry | UNKNOWN |
| Molecular Formula | C17H26NO3.Cl |
| Molecular Weight | 327.846 |
| Optical Activity | ( - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].C[NH+](C)CCOC(=O)C(C1=CC=CC=C1)C2(O)CCCC2
InChI
InChIKey=RHKZVMUBMXGOLL-UHFFFAOYSA-N
InChI=1S/C17H25NO3.ClH/c1-18(2)12-13-21-16(19)15(14-8-4-3-5-9-14)17(20)10-6-7-11-17;/h3-5,8-9,15,20H,6-7,10-13H2,1-2H3;1H
DescriptionCurator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003519
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/mesh/68003519
Cyclopentolate (cyclopentolate hydrochloride) is a parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia. This anticholinergic preparation blocks the responses of the sphincter muscle of the iris and the accommodative muscle of the ciliary body to cholinergic stimulation, producing pupillary dilation (mydriasis) and paralysis of accommodation (cycloplegia). It acts rapidly, but has a shorter duration than atropine. Maximal cycloplegia occurs within 25 to 75 minutes after instillation. Complete recovery of accommodation usually takes 6 to 24 hours. Complete recovery from mydriasis in some individuals may require several days. Heavily pigmented irides may require more doses than lightly pigmented irides.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094109 |
10.0 nM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Diagnostic | PENTOLAIR Approved UseCyclopentolate Hydrochloride Ophthalmic Solution is used to produce mydriasis and cycloplegia in diagnostic procedures. Launch Date1994 |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.8 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8512760 |
2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered: |
CYCLOPENTOLATE HYDROCHLORIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
324 ng × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8512760 |
2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered: |
CYCLOPENTOLATE HYDROCHLORIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
112 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/8512760 |
2 drop single, ocular dose: 2 drop route of administration: Ocular experiment type: SINGLE co-administered: |
CYCLOPENTOLATE HYDROCHLORIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: Page: e704 |
unknown, 90 days n = 1 Health Status: unknown Condition: mydriasis induction Age Group: 90 days Sex: F Population Size: 1 Sources: Page: e704 |
Other AEs: Vomiting, Cyanosis... Other AEs: Vomiting Sources: Page: e704Cyanosis Respiratory distress |
2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
Other AEs: Ataxia, Disorder speech... Other AEs: Ataxia Sources: Disorder speech Restlessness Hallucinations Hyperactivity Seizures Confusion and disorientation Other specified visual disturbances |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Cyanosis | 1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: Page: e704 |
unknown, 90 days n = 1 Health Status: unknown Condition: mydriasis induction Age Group: 90 days Sex: F Population Size: 1 Sources: Page: e704 |
|
| Respiratory distress | 1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: Page: e704 |
unknown, 90 days n = 1 Health Status: unknown Condition: mydriasis induction Age Group: 90 days Sex: F Population Size: 1 Sources: Page: e704 |
|
| Vomiting | 1 % 1 times / 5 min multiple, topical Overdose Dose: 1 %, 1 times / 5 min Route: topical Route: multiple Dose: 1 %, 1 times / 5 min Sources: Page: e704 |
unknown, 90 days n = 1 Health Status: unknown Condition: mydriasis induction Age Group: 90 days Sex: F Population Size: 1 Sources: Page: e704 |
|
| Ataxia | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Confusion and disorientation | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Disorder speech | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Hallucinations | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Hyperactivity | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Other specified visual disturbances | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Restlessness | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
|
| Seizures | 2 % single, topical Recommended Dose: 2 % Route: topical Route: single Dose: 2 % Sources: |
unknown Health Status: unknown Condition: mydriasis induction Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Cyclopentolate and grand mal seizure. | 1999 |
|
| Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. | 2000 Aug |
|
| Systemic toxicity with cyclopentolate eye drops. | 2000 Mar |
|
| Haploinsufficient Bmp4 ocular phenotypes include anterior segment dysgenesis with elevated intraocular pressure. | 2001 |
|
| Herpes simplex virus bullous keratitis misdiagnosed as a case of pseudophakic bullous keratopathy with secondary glaucoma: an unusual presentation. | 2001 |
|
| Retinoscopy in infants using a near noncycloplegic technique, cycloplegia with tropicamide 1%, and cycloplegia with cyclopentolate 1%. | 2001 Apr |
|
| Randomised controlled trial of ketorolac in the management of corneal abrasions. | 2001 Apr |
|
| Acute gastric dilatation complicating the use of mydriatics in a preterm newborn. | 2001 Aug |
|
| Does instilling proxymetacaine before cyclopentolate significantly reduce stinging? The implications of paediatric cycloplegia. | 2001 Feb |
|
| [Experiences with cycloplegic drops in German-speaking centers of pediatric ophthalmology and stabology--results of a 1999 survey]. | 2001 Jan |
|
| Ocular injury from the venom of the Southern walkingstick. | 2001 Jan |
|
| [Biochemical stress monitoring during cataract surgery; phenylephrine 10% shows no changes in serum-catecholamines in comparison with phenylephrine 5%]. | 2001 Jul |
|
| Valsalva retinopathy-like hemorrhage associated with combined trabeculotomy-trabeculectomy in a patient with developmental glaucoma. | 2001 Jul-Aug |
|
| Cycloplegic refractions in healthy children aged 1 through 48 months. | 2001 Nov |
|
| Repeat cycloplegic examinations at the Naval Operational Medicine Institute. | 2001 Sep |
|
| [Variability in the effects of topical cycloplegics]. | 2002 Jun |
|
| [Full optical correction after cycloplegia in headache]. | 2002 Mar |
|
| Prednisolone and flurbiprofen drops to maintain mydriasis during phacoemulsification cataract surgery. | 2003 Dec |
|
| Wavefront analysis in eyes with accommodative spasm. | 2003 Dec |
|
| Comparison of measurements of refractive errors between the hand-held Retinomax and on-table autorefractors in cyclopleged and noncyclopleged children. | 2003 Dec |
|
| Surgically induced miosis during phacoemulsification in patients with diabetes mellitus. | 2003 Mar |
|
| Herpes zoster virus sclerokeratitis and anterior uveitis in a child following varicella vaccination. | 2003 Mar |
|
| Transient paralytic ileus following the use of cyclopentolate-phenylephrine eye drops during screening for retinopathy of prematurity. | 2003 May-Jun |
|
| Use of a wick to deliver preoperative mydriatics for cataract surgery. | 2003 Nov |
|
| Topical mydriatic and cycloplegic spray for Chinese children. | 2003 Nov-Dec |
|
| Evaluation of surgical performance with intracameral mydriatics in phacoemulsification surgery. | 2004 Apr |
|
| Keratitis due to a coelomycetous fungus: case reports and review of the literature. | 2004 Jan |
|
| Angioedema related to the use of hyaluronidase in cataract surgery. | 2004 Jul |
|
| The effect of off-the-visual-axis retinoscopy on objective refractive measurement. | 2004 Jun |
|
| Comparison of tropicamide and cyclopentolate for cycloplegic refractions in myopic adult refractive surgery patients. | 2005 Apr |
|
| Effect of (+) or (-) camphorsulfonic acid additives to the mobile phase on enantioseparations of some basic drugs on a Chiralcel OD column. | 2005 Aug 12 |
|
| Cholinergic innervation of the mouse isolated vas deferens. | 2005 Dec |
|
| Lack of efficacy of dilated screening for retinoblastoma. | 2005 Jul-Aug |
|
| Macular star associated with Behçet disease. | 2006 Apr |
|
| Cataractous changes due to posterior chamber flattening with a posterior chamber phakic intraocular lens secondary to the administration of pilocarpine. | 2006 Aug |
|
| Pseudophakic accommodation with 2 models of foldable intraocular lenses. | 2006 Feb |
|
| A comparison of autorefraction and subjective refraction with and without cycloplegia in primary school children. | 2006 Jul |
|
| Effects of mydriatics on intraocular pressure and pupil size in the normal feline eye. | 2006 Jul-Aug |
|
| Pseudallescheria boydii keratitis. | 2006 Mar-Apr |
|
| A preoperative mixture of anesthetic jelly, dilating drops, antibiotics, and anti-inflammatories for cataract surgery. | 2006 May-Jun |
|
| [Neurotoxic effects induced by the topical administration of cycloplegics. A case report and review of the literature]. | 2006 Nov 16-30 |
|
| Cataract surgery management in patients taking tamsulosin staged approach. | 2006 Oct |
Patents
Sample Use Guides
Instill one or two drops of 1% solution in the eye which may be repeated in five to ten minutes if necessary. Complete recovery usually occurs in 24 hours. Complete recovery from mydriasis in some individuals may require several days.
Route of Administration:
Other
Cultured human corneal epithelial cells showed high-affinity, specific binding to the muscarinic cholinergic antagonist, 3H-quinuclidinyl benzilate (3H-QNB). The binding sites had a dissociation constant of 3.9 nM and a maximal binding capacity of 880 fmol bound/mg protein. Other muscarinic antagonists (cyclopentolate and atropine) effectively competed for binding with 3H-QNB at low concentrations (IC50 = 10 nM).
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
60452-44-0
Created by
admin on Sat Dec 16 10:25:50 GMT 2023 , Edited by admin on Sat Dec 16 10:25:50 GMT 2023
|
PRIMARY | |||
|
DTXSID60975861
Created by
admin on Sat Dec 16 10:25:50 GMT 2023 , Edited by admin on Sat Dec 16 10:25:50 GMT 2023
|
PRIMARY | |||
|
0UXD5V5G6V
Created by
admin on Sat Dec 16 10:25:50 GMT 2023 , Edited by admin on Sat Dec 16 10:25:50 GMT 2023
|
PRIMARY | |||
|
22162
Created by
admin on Sat Dec 16 10:25:50 GMT 2023 , Edited by admin on Sat Dec 16 10:25:50 GMT 2023
|
PRIMARY | |||
|
262-240-4
Created by
admin on Sat Dec 16 10:25:50 GMT 2023 , Edited by admin on Sat Dec 16 10:25:50 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD
